Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million init ... Subscribe now to see this Premium News article from Alliance News ...

BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

In September 2024, BioAge received approximately $189.5 million in net proceeds from its initial public offering and concurrent private placement. In October 2024, the underwriters of BioAge's IPO ...

with a 40% probability of success, via peak penetration of 15% as an add-on therapy in the incretin-treated market. BioAge (BIOA) held an upsized initial public offering on Sept. 26, raising $198M.

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...

(Reuters) -Biotech firm Septerna on Thursday said it raised $288 million in its initial public offering that has been upsized twice ... MBX Biosciences, BioAge Labs and Upstream Bio are also ...